SoftBank Vision Fund 2 led the healthcare management software provider’s series D round, taking its overall funding to about $213m and its valuation to a reported $1.4bn.
Category: Size
Data.World aggregates $50m for series C
Prologis Ventures has returned to back the Associated Press, Samsung Next and Workday Ventures-backed business data software developer’s latest round, hiking its funding to over $132m in total.
IntelyCare nurses $115m in series C funding
Kaiser Permanente Ventures returned to reinvest in the nursing staff management service at a $1.1bn valuation.
Daily Deal Round Up: April 6, 2022
Crypto.com, Huobi and BitMart invested in cryptocurrency scaling technology developer Boba Network at a $1.5bn valuation while natural fibre composite provider Bcomp netted $34.9m in a BMW-led round.
AMD to pick up Pensando for $1.9bn
HPE, Alphabet, Ericsson, Qualcomm, Oracle, Liberty Global and NetApp are set to exit the edge computing technology provider.
Climeworks clasps $646m
Swiss Re was among the participants in a round which pushed the carbon capture system developer’s overall financing past the $800m mark.
Softbank helps send $300m to Remote
The remote work software provider received $300m in a round led by SoftBank Vision Fund 2 valuing it at almost $3bn.
Microba makes tracks to ASX
The Macrogen-backed gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.
Tokocrypto spreads blockchain investments
The Binance-backed cryptocurrency exchange has put its weight behind Nanovest, Avarik Saga, Avarta, Diamond Protocol and Play it Forward DAO
Daily Deal Round Up: April 5, 2022
Fertility financing service Future Family, machine learning software developer Black Crow AI and digital twin software provider vHive each nabbed $25m in corporate-backed rounds.
Labster boosts series C to $107m
The Swisscom-backed round was buttressed with an additional $47m to support the virtual experiment provider’s expansion plans.
LinkSquares puts together $100m series C
Xerox, Bottomline Technologies and Massachusetts Mutual were potentially among the investors in a round valuing the contract analytics software developer at $800m.
Adaptive Phage grows series B to $61m
AMR Action Fund added $20m to a round for the drug-resistant bacteria treatment developer following a Mayo Clinic-backed first close last May.
RecBio delivers IPO
The China Resources and Legend Holdings-backed vaccine technology developer floated in Hong Kong in a $97.7m offering following nearly $460m in funding.